SCHEMBL3014549

SCHEMBL3014549

COc1ccc(S(=O)(=O)C2CCN(c3nc(-c4ccc(Cl)cc4Cl)cs3)CC2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 3/20 0.53
RAB9A P51151 4/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
MAPT P10636 4/20 0.45
USP2 O75604 1/20 0.43
RECQL P46063 1/20 0.43
HSD17B10 Q99714 1/20 0.43
NPC1 O15118 2/20 0.43
POLB P06746 1/20 0.42
NPSR1 Q6W5P4 2/20 0.42
ALDH1A1 P00352 3/20 0.41
LMNA P02545 2/20 0.41
MAPK1 P28482 2/20 0.41
PLAU P00749 1/20 0.40
KCNQ1 P51787 2/20 0.40
MEN1 O00255 1/20 0.40
GAA P10253 1/20 0.40
KMT2A Q03164 1/20 0.40
MMP1 P03956 1/20 0.40
MMP3 P08254 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3017157 0.91 AR (0.60) ARRAB9ASMN1; SMN2MAPTNPC1
SCHEMBL3018834 0.90 AR (0.56) ARRAB9ASMN1; SMN2MAPTNPC1
SCHEMBL3015459 0.89 AR (0.52) ARRAB9ASMN1; SMN2MAPTUSP2
SCHEMBL3018986 0.88 AR (0.51) ARRAB9ASMN1; SMN2MAPTUSP2
SCHEMBL3014441 0.88 AR (0.48) ARRAB9ASMN1; SMN2MAPTUSP2
SCHEMBL3002625 0.88 AR (0.56) ARRAB9ASMN1; SMN2MAPTNPC1
SCHEMBL3002708 0.88 AR (0.56) ARRAB9ASMN1; SMN2MAPTUSP2
SCHEMBL3009932 0.88 AR (0.50) ARRAB9ASMN1; SMN2MAPTUSP2
SCHEMBL3017543 0.88 AR (0.50) ARRAB9ASMN1; SMN2MAPTUSP2
SCHEMBL3021277 0.87 AR (0.60) ARRAB9ASMN1; SMN2MAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA AR 3801/4885RAB9A 2943/4885SMN1; SMN2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.